Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial [0.03%]
利什曼综合征携带者的癌症预防型Nous-209新抗原疫苗：Ib/II期临床试验
Anna Morena D&#x;Alise,Jason Willis,Fahriye Duzagac et al.
Anna Morena D&#x;Alise et al.
Cancer interception is a preventative approach aiming to reduce cancer incidence by targeting precancers and early-stage cancers. Lynch syndrome (LS) is a prevalent hereditary cancer syndrome affecting ~1 in 300 individuals, with an overall...
Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study [0.03%]
204个国家和地区1990年~2023年的苯丙胺、大麻、可卡因和阿片类物质使用负担：全球疾病负担研究
Jiseung Kang,Hyeon Jin Kim,Min Seo Kim;GBD Substance Use Collaborators;Jae Il Shin et al.
Jiseung Kang et al.
Drug use disorders (DUDs) are emerging global public health challenges. Here we investigated the global and regional estimates of the prevalence and burden of DUDs, including amphetamine, cannabis, cocaine and opioid use disorders, from 199...
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial [0.03%]
阿贝西利治疗NF2或CDK通路异常的脑膜瘤： Alliance A071401二期临床试验结果
Priscilla K Brastianos,Katharine Dooley,Susan Geyer et al.
Priscilla K Brastianos et al.
Systemic treatments are limited for patients with meningiomas that have progressed after surgery or radiation. Loss of NF2 and CDKN2A/CDKN2B is common in higher-grade meningiomas and promotes progression in preclinical models. We evaluated ...
Sabin Nsanzimana,Yvan Butera,Menelas Nkeshimana et al.
Sabin Nsanzimana et al.
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial [0.03%]
一种口服、肝特异性的LXR反向激动剂用于脂质异常的临床前研究及I期临床试验
Xiaoxu Li,Giorgia Benegiamo,Archana Vijayakumar et al.
Xiaoxu Li et al.
Despite advances in lipid-lowering treatment, atherosclerotic cardiovascular disease remains the leading cause of mortality, underscoring the need to address residual risk. Targeting both the synthesis and clearance of triglyceride (TG)-ric...
The new vision from the National Institute of Allergy and Infectious Diseases (NIAID) [0.03%]
美国过敏症和传染病研究所(NIAID)的新视野
Jeffery K Taubenberger,John H Powers,Jay Bhattacharya
Jeffery K Taubenberger
Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy [0.03%]
肝腺相关病毒基因治疗后出现质粒污染序列和载体基因组断裂的现象
Sarah Buddle,Li-An K Brown,Sofia Morfopoulou et al.
Sarah Buddle et al.
Adeno-associated viruses (AAVs) are common vectors in gene therapy but can frequently cause liver complications in patients. The mechanisms underlying AAV-related liver toxicity remain poorly understood, posing challenges for effective prev...
External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial [0.03%]
青年人ADHD外周三叉神经刺激治疗II期临床试验
Aldo Alberto Conti,Natali Bozhilova,Irem Ece Eraydin et al.
Aldo Alberto Conti et al.
External trigeminal nerve stimulation (TNS) received US Food and Drug Administration clearance in 2019 as the first device-based, non-pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), based on a small pilot sham...